Inventia Life Science Accelerates Growth With $25M Series B And Launches 3D Cell Culture Platform Into Us Market
Inventia Life Science Accelerates Growth With $25M Series B And Launches 3D Cell Culture Platform Into Us Market
12/15/21, 1:00 PM
Location
sydneyMoney raised
$25 million
Industry
biotechnology
science and engineering
Round Type
series b
Inventia Life Science, a world leader in advanced 3D cell cultures for research and clinical purposes, has today announced the close of a US $25M Series B funding round, led by Blackbird Ventures. Inventia has also announced the launch of its US operations with the appointment of Dwayne Dexter as its Director of US Sales. Through this Series B round of financing, Inventia plans to market its RASTRUMTM 3D cell culture platform worldwide and grow its team from 36 to 150 employees by the end of 2024. In particular, it aims to develop a strong presence in the US, where the biomedical research and drug discovery markets are currently estimated to be worth more than US $40 billion
Company Info
Location
sydney, new south wales, australia
Additional Info
At Inventia, we’re creating some of the most powerful tools for advanced biomedical discovery today. We build printers and formulate bioinks that together allow human cells to be printed in 3 dimensional structures and help forward-thinking pioneers in the fields of cancer research, drug discovery and medicine to create human tissue for research and therapy purposes. Our RASTRUM™ platform creates 3D cell cultures which imitate real human tissue in terms of its structure and behaviour across a range of disease states. The physiological complexity of these cell cultures provides an environment in which world-class research and discovery can occur, right in the researcher’s own lab. Inventia Life Science Pty Ltd was the vision of Dr. Julio Ribeiro and founded by him with Dr. Aidan O'Mahony, Dr. Cameron Ferris and Peter Arthur in 2013 and is headquartered in Sydney, Australia.